18
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Beyond Biology: The Crucial Role of Sex and Gender in Oncology

      Submit here before May 31, 2024

      About Oncology Research and Treatment: 2.4 Impact Factor I 3.3 CiteScore I 0.495 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      A Geographic Area with Better Outcome of Esophageal Carcinoma: Is There an Effect of Ethnicity and Etiologic Factors?

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objectives: Although Iran, and especially the northeast of the country, is known as one of the areas in the world where esophageal cancer is most prevalent, there is no information on the survival rate of patients affected with this disease in this region. To address this issue, we conducted a study comprehensive enough to provide as accurate an estimate as possible. Any finding related to survival of patients in this area may be considered representative of Iran. Methods: Esophageal cancer patients who were consecutively referred to the oncology centers of Omid and Imam Reza Hospitals from July 1997 to March 2004 were recruited for the study. Data collection included the demographical and clinical characteristics of patients in addition to treatment details. The median survival and overall survival rates, as well as the median event-free survival and event-free survival rates, were evaluated. Univariate and multivariate analyses were performed to detect any significant prognostic factors. Results: 1,568 patients were eligible. The Kaplan-Meier analysis indicates that median survival is 38 months (95% CI, 26.6–49.3), 5-year survival is 42% (38.76–46.16%), median event-free survival is 21 months (95% CI, 18.2–23.8) and 5-year event-free survival is 29.9% (27.07–32.67%). The univariate analysis indicates that age, gender, tumor histology, tumor location, body mass index and disease stage are significant predictors of overall survival. However, in the multivariate analysis, disease stage is the best prognostic factor. Conclusion: The prognosis of esophagus cancer in Iran is not as dismal as in other world regions. Our treatment outcome and survival rates are much higher than those reported especially in western countries.

          Related collections

          Most cited references9

          • Record: found
          • Abstract: found
          • Article: not found

          Radical lymph node dissection for cancer of the thoracic esophagus.

          The authors documented the localization and frequency of lymphatic spread in squamous cell carcinoma of the thoracic esophagus and evaluated the influence of radical systematic lymph node dissection on patient survival. From accumulated surgical experience, it was suggested that some of the patients with lymph nodal involvement from cancer could be cured by its clearance. However, it is only recently that cancer of the esophagus has been evaluated in terms of analyzing lymphatic spread and results of lymphadenectomy. Among 1298 patients admitted to the Toranomon Hospital between 1973 and 1993, 913 (70.3%) had resections, including curative and palliative procedures. For this study, 717 patients with TNM RO (resection with no residual tumor at operation in TNM classification) were analyzed. Survival was compared between groups of patients with less extensive thoracoabdominal (two-field) dissections and extensive collothoracoabdominal (three-field) dissections. Comparative study revealed that 5-year survival rate for TNM RO patients after free-field dissection (55.0%) was significantly better (log rank test, p = 0.0013) than the rate after two-field dissection (38.3%). The results were particularly significant in subgroups with stage III and IV (because of nodal factor). Overall 5-year survival rate after all resections was 42.4%. The role of radical lymph node dissection in cancer of the thoracic esophagus evaluated. Long-term survival was compared between two groups with two- and three-field dissection. It was concluded that survival rate was significantly better in patients with extensive three-field dissection.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Epidemiology of upper gastrointestinal malignancies.

            The demographics of esophageal and gastric cancer have been changing dramatically in the United States over the past several decades. While incidence rates for esophageal squamous cell carcinoma and distal gastric carcinoma have been declining, the trends for adenocarcinoma of the esophagus and proximal stomach have been rising rapidly, particularly among white males. The incidence of these upper gastrointestinal (GI) malignancies varies widely based on geographic location, race, and socioeconomic status. The primary causes of squamous cell carcinoma of the esophagus are tobacco use and alcohol consumption, whereas the main risk factors for adenocarcinoma of the esophagus are gastroesophageal reflux disease and obesity. Dietary factors and Helicobacter pylori infection play an important role in the development of gastric cancer. Understanding the epidemiology and etiologies of esophageal and gastric carcinomas will lead to the development of interventions for screening and prevention in high-risk populations.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              National Cancer Data Base report on esophageal carcinoma.

              The prognosis for patients with esophageal carcinoma is poor, with less than fifty percent surviving 1 year after diagnosis. Although diagnostic and staging methods have improved, a large proportion of patients present with advanced disease. Research is being conducted to determine what multimodality treatment regimens provide the best local control and survival. Using the National Cancer Data Base's most current accrual of oncologic data for cases diagnosed in 1988 and 1993, patterns of care and outcome were analyzed for esophageal carcinoma. A substantial increase was demonstrated between 1988 and 1993 in the proportion of esophageal adenocarcinomas and patients presenting with Stage IV disease. The therapeutic regimen most frequently employed in 1993 was combined radiation therapy and chemotherapy, which rose 8.2% from 2.2% in 1988. The dramatic rise across the years of this study in the occurrence of esophageal adenocarcinomas indicates a need for developing strategies to evaluate Barrett's preneoplastic mucosal changes more precisely. The increasing use of combined chemotherapy and radiation therapy reflects the results of randomized trials that have demonstrated improved response and outcome for this combined regimen compared with radiation therapy alone. There was no substantial increase in the use of surgical resection with chemotherapy and radiation therapy throughout these years.
                Bookmark

                Author and article information

                Journal
                OCL
                Oncology
                10.1159/issn.0030-2414
                Oncology
                S. Karger AG
                0030-2414
                1423-0232
                2009
                September 2009
                30 July 2009
                : 77
                : 3-4
                : 172-177
                Affiliations
                Departments of aRadiation Oncology, bMedical Statistics and cSurgery, Mashhad University of Medical Sciences, Mashhad, dDepartment of Radiation Oncology, Kerman University of Medical Sciences, Kerman, eDepartment of Radiation Oncology, Ardabil University of Medical Sciences, Ardabil, Iran
                Article
                231887 Oncology 2009;77:172–177
                10.1159/000231887
                19641336
                0ef3e9ef-2943-4283-b09b-53abf9f388dc
                © 2009 S. Karger AG, Basel

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                History
                : 09 October 2008
                : 23 March 2009
                Page count
                Figures: 2, Tables: 2, References: 23, Pages: 6
                Categories
                Reducing the Worldwide Burden of Cancer

                Oncology & Radiotherapy,Pathology,Surgery,Obstetrics & Gynecology,Pharmacology & Pharmaceutical medicine,Hematology
                Prognostic factors,Outcome,Esophagus cancer,Iran

                Comments

                Comment on this article